🇺🇸 FDA
Patent

US 7981610

ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)

granted A61PA61P35/02

Quick answer

US patent 7981610 (ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jul 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61P, A61P35/02